Takeda Pens Mid-Trial Settlement To Dismiss US Colcrys Antitrust Suit
Trio Of Generics Manufacturers Named In 2021 Suit Which Alleges Conspiracy Over Colchicine
Japanese originator Takeda has agreed to settle two-year-old anticompetitive claims lodged by wholesalers in the US that it conspired with several generics manufacturers to maintain supracompetitive pricing for its Colcrys branded treatment for gout.
You may also be interested in...
Endo has realised plans to launch an authorised generic of Takeda’s Colcrys (colchicine) 0.6mg tablets through its Par Pharmaceutical subsidiary, under a prior US supply and distribution agreement involving the Endo Ventures affiliate.
Presenting nine-month financial results, Krka disclosed a new slate of strategic objectives stretching out until 2028 – including a tacit admission that its current EBITDA margin may not be sustainable.
Aspen has underlined previously its commitment to building on its business in China, and now it has done so, picking up Sandoz’s local operations for up to €92.6m, while bringing in cash by offloading a quartet of anesthetics in Europe back to the firm.